Cepheid Turns to Profit in 4Q - Analyst Blog
January 25 2013 - 5:50AM
Zacks
Cepheid (CPHD)
reported net income of $5.6 million or 8 cents per share in the
fourth quarter of 2012, a significant improvement from net loss of
$1.6 million or 3 cents per share in the year-ago quarter. After
adjusting for amortization and impairment expenses, the company
reported earnings per share of 11 cents, better than the Zacks
Consensus Estimate of break-even earnings per share and 6 cents per
share in the year-ago quarter.
For 2012, adjusted loss per share
came in at 4 cents compared with earnings of 15 cents per share in
2011. The adjusted figures take into account litigation settlement
incurred in 2012. The Zacks Consensus was pegged at a loss of 39
cents per share.
Quarter in
Detail
Revenues increased 15.4% year over
year to $92.4 million in the fourth quarter. Growth was
single-handedly led by commercial clinical franchise. As per the
preliminary results reported earlier this month, the company
expected revenues to be in the neighborhood of $92 million,
trailing the then Zacks Consensus Estimate of $94 million.
For 2012, revenues surged 19.3%
year over year to $331.2 million, marginally missing the Zacks
Consensus Estimate of $332 million.
Among the segments, the Clinical
segment (up 19% year over year to $82.2 million) consisting of
Clinical Systems (down 33% to $13.4 million) and Clinical Reagents
(up 40% to $68.8 million) contributed about 89% of the total sales
in the quarter. Cepheid’s Non-Clinical business declined 6% year
over year to $7.5 million.
On a geographic basis, product
sales from North America grew 13% year over year to $60.4 million
whereas overseas market recorded a 26% year-over-year surge to
$29.3 million.
Placements of Cepheid’s GeneXpert
systems were lower during the reported quarter with 153 systems
(175 in the year-ago quarter) taking the total number of placements
to 523 systems in 2012. Placements as part of the High Burden
Developing Country (‘HBDC’) program were lower at 68 (181 in the
prior year quarter) due to manufacturing issues and choppy demand
from the HBDC countries. This takes the annual total to 506
placements. Including the HBDC systems, a cumulative 3,835 systems
(compared with 2,843 systems at the end of 2011) have been placed
worldwide as of Dec 31, 2012.
Gross margin was 54% in the
reported quarter, up 200 basis points (bps) from the year-ago
period. The margin expansion was on account of favorable mix and
lower negative impact from manufacturing disruptions.
Operating expenses amounted to
$43.1 million, up 4.3% year over year, driven by higher research
and development (up 3.9% year over year to $17.3 million) as well
as sales and marketing (up 12.4% to $16.3 million) expenditure,
partially offset by lower general and administrative (down 6.7% to
$9.5 million) expenses. Operating margin came in at 7% compared
with 0.2% in the year-ago quarter. Adjusted income from operations
was $13.9 million or 15% of total revenues in the fourth
quarter.
Outlook
Cepheid issued guidance for 2013.
It expects revenues in the range of $375–$385 million. The company
expects the 2013 adjusted earnings per share (considering the stock
based compensation as a regular expense) in the range of 1 cent–7
cents. The current Zacks Consensus Estimate of $396 million for
revenues and earnings per share of 12 cents remain outside the said
band.
Recommendation
While we believed that Cepheid’s
manufacturing concerns were temporary and waning, the company’s
return to profitability encourages our confidence. Cepheid should
further benefit from surging demand for its offerings. The company
is currently focused to meet the higher demand for its Xpert Flu
test due to a burdensome flu season.
Cepheid should further gain from
normal manufacturing operations after addressing the underlying
issues, which negatively affected the financial results in the
second half of 2012. Moreover, it plans to triple its production
capacity in 2013. As the headwinds take a backseat, we look forward
to the company’s performance in 2013. However, seasonality trends,
variability in HBDC revenues and a weak capital spending
environment keeps us on the sidelines.
The stock carries a Zacks Rank #3
(Hold) in the short-term. While we have a non-committal stance on
Cepheid, we look forward to the results of Cantel
Medical (CMN), Cyberonics (CYBX) and
Delcath Systems (DCTH), each carrying a Zacks Rank
#1 (Strong Buy).
CANTEL MED CORP (CMN): Free Stock Analysis Report
CEPHEID INC (CPHD): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jul 2023 to Jul 2024